A new study explores the possibility of using xenograft-based platform-independent gene signatures to predict patient response to chemotherapy, radiation, and combination therapy for glioblastoma.
The US Food and Drug Administration recently approved the use of selinexor (XPOVIO) in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma.
Cancer Network spoke with Fergus Couch, PhD, professor and researcher at the Mayo Clinic, about new genes implicated in triple-negative breast cancer risk.
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: MultiMedia Healthcare
535 Connecticut Avenue, Suite 300
Norwalk, CT, 06854, USA
